JP Morgan Chase
OVID icon

JP Morgan Chase’s Ovid Therapeutics OVID Stock Holding History

JP Morgan Chase’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$310 Hold
147
– – ﹤0.01% 7222
2025
Q4 		$240 Sell
147
-2,792
-95% -$4.3K ﹤0.01% 7141
2025
Q3 		$3.82K Sell
2,939
-2,508
-46% -$2.17K ﹤0.01% 6813
2025
Q2 		$1.8K Sell
5,447
-1,203,177
-100% -$363K ﹤0.01% 6552
2025
Q1 		$377K Sell
1,208,624
-209,682
-15% -$129K ﹤0.01% 4941
2024
Q4 		$1.32M Sell
1,418,306
-45,532
-3% -$51K ﹤0.01% 4430
2024
Q3 		$1.73M Sell
1,463,838
-2,595
-0.2% -$2.71K ﹤0.01% 4115
2024
Q2 		$1.13M Sell
1,466,433
-111,628
-7% -$311K ﹤0.01% 4192
2024
Q1 		$4.81M Sell
1,578,061
-53,681
-3% -$180K ﹤0.01% 3145
2023
Q4 		$5.25M Buy
1,631,742
+18,333
+1% +$62.7K ﹤0.01% 3046
2023
Q3 		$6.2M Buy
1,613,409
+1,565,762
+3,286% +$5.63M ﹤0.01% 2672
2023
Q2 		$156K Buy
47,647
+45,791
+2,467% +$155K ﹤0.01% 5228
2023
Q1 		$5K Hold
1,856
– – ﹤0.01% 6253
2022
Q4 		$4K Sell
1,856
-2,609
-58% -$4.45K ﹤0.01% 6211
2022
Q3 		$8K Buy
4,465
+1,427
+47% +$2.99K ﹤0.01% 6006
2022
Q2 		$7K Sell
3,038
-5,009
-62% -$12.1K ﹤0.01% 6102
2022
Q1 		$25K Buy
8,047
+1,934
+32% +$6.08K ﹤0.01% 6023
2021
Q4 		$20K Buy
6,113
+1,231
+25% +$4.22K ﹤0.01% 6222
2021
Q3 		$16K Buy
4,882
+1,634
+50% +$5.96K ﹤0.01% 6094
2021
Q2 		$13K Sell
3,248
-14,680
-82% -$57.9K ﹤0.01% 6001
2021
Q1 		$72K Sell
17,928
-3,136
-15% -$10.4K ﹤0.01% 5458
2020
Q4 		$49K Buy
21,064
+5,104
+32% +$23.8K ﹤0.01% 5160
2020
Q3 		$95K Sell
15,960
-8,356
-34% -$55.9K ﹤0.01% 4717
2020
Q2 		$179K Sell
24,316
-60,537
-71% -$283K ﹤0.01% 4315
2020
Q1 		$253K Sell
84,853
-134,876
-61% -$455K ﹤0.01% 4164
2019
Q4 		$912K Buy
219,729
+122,336
+126% +$386K ﹤0.01% 3927
2019
Q3 		$316K Buy
97,393
+27,167
+39% +$61.7K ﹤0.01% 4397
2019
Q2 		$129K Sell
70,226
-23,865
-25% -$42.6K ﹤0.01% 4832
2019
Q1 		$167K Sell
94,091
-40,236
-30% -$101K ﹤0.01% 4704
2018
Q4 		$325K Buy
134,327
+79,495
+145% +$363K ﹤0.01% 4352
2018
Q3 		$311K Buy
54,832
+31,687
+137% +$240K ﹤0.01% 4512
2018
Q2 		$181K Sell
23,145
-9,861
-30% -$84.6K ﹤0.01% 4599
2018
Q1 		$233K Buy
33,006
+27,343
+483% +$221K ﹤0.01% 4319
2017
Q4 		$56K Buy
+5,663
New +$52K ﹤0.01% 4856

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

JP Morgan Chase's OVID Position: Q1 2026 in Review

JP Morgan Chase held its Ovid Therapeutics (OVID) position steady in Q1 2026 at 147 shares worth $310. The position accounts for ﹤0.01% of the portfolio, ranked #7222.

JP Morgan Chase first reported a position in OVID in Q4 2017 and has held it in 34 quarters since. The position peaked at $6.2M in Q3 2023. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • JP Morgan Chase held 147 shares of Ovid Therapeutics worth $310 as of Q1 2026.
  • JP Morgan Chase left its Ovid Therapeutics share count unchanged in Q1 2026.
  • Ovid Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7222 holding.
  • JP Morgan Chase first reported a position in Ovid Therapeutics in Q4 2017 and has held it in 34 quarters since.
  • JP Morgan Chase's Ovid Therapeutics position peaked at $6.2M in Q3 2023.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.